Novel cyclosporins
Patent 4703033 Issued on October 27, 1987. Estimated Expiration Date: 
March 7, 2006. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
March 7, 2006. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.InventorAssigneeApplicationNo. 06/837434 filed on 03/07/1986US Classes:514/11, Monocyclic530/317, Cyclic peptides530/321, Containing only normal peptide links in the ring, i.e., homodetic cyclic peptides930/190, Antibiotic930/20, Containing modified or unusual amino acid (See note 1 and note 2)930/21, Containing D-amino acid930/270Cyclic peptide or cyclic protein (See note 8)ExaminersPrimary: Phillips, Delbert R.Attorney, Agent or FirmInternational ClassesC07K 7/64 (20060101)C07K 7/00 (20060101) A61K 38/00 (20060101) Foreign Application Priority Data1985-03-11 GBAbstractCyclosporins e.g. of formula II ##STR1## in which X is -MeBmt- or -dihydro-MeBmt- andY is -u-, -Thr-, -Val- or -Nva-,wherein the residue at the 3-position, i.e. the residue Z in formula II, is an optically active, -N-methylated -amino acid residue of the (D)-configuration, possess pharmaceutical, in particular immunosuppressive, anti-inflammatory and anti-parasitic activity. Intermediate cyclosporin poly-anions having a de-protonated sarcosyl residue at the 3-position, e.g. polyanions of cyclosporins of formula II above wherein X and Y have the meanings given above and Z is -Sar-, in which the said residue Z is de-protonated, are also novel and part of the invention.Other References
|
| ||||||||||||||
